ALNA News and Press, Allena Pharmaceuticals Inc. From 11/25/19

NEWTON, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...

Allena Pharmaceuticals ( ALNA ) was founded in 2011 and is based in Newton, Massachusetts. The company's development pipeline is focused on the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney diseases. Its lead product candidate is Reloxa...

Allena Pharmaceuticals (NASDAQ: ALNA ): Q3 GAAP EPS of -$0.57 misses by $0.07 . More news on: Allena Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

 -- Reported Positive Topline Results from Pivotal Phase 3 URIROX-1 Trial of Reloxaliase in Enteric Hyperoxaluria (EH), with Statistically Significant Reduction in Urinary Oxalate (UOx) Compared to Placebo -- -- Reported Positive Data from Study 206 of Reloxaliase, Demonstrating S...

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) had a rocky time last week, starting at 3,467.3 points and reaching a low of 3,396.02 points on Thursday (November 7). By Friday (November 8), the index had recovered slightly to reach 3,454.53 points as of 1:59 p.m. EST. On Tuesday (...

The following slide deck was published by Allena Pharmaceuticals, Inc. in conjunction with this Read more ...

Dermira (NASDAQ: DERM ) +29%  on apparent reaction to AnaptysBio's  etokimab flop  in a mid-stage atopic dermatitis study. More news on: Dermira, Inc., ObsEva SA, Sientra, Inc., Stocks on the move, Read more ...

Shares of Allena Pharmaceuticals (NASDAQ: ALNA ) crumbled during Thursday’s (November 7) trading session despite the company releasing positive results from two of its clinical trials evaluating its lead drug candidate, reloxaliase. In a press release, the company said both studies...

Thinly traded nano cap Allena Pharmaceuticals ( ALNA -46.7% ) is getting roughed up on a 22x surge in volume in reaction to results from two clinical trials evaluating lead candidate reloxaliase (ALLN-177) in patients with a fat malabsorption disorder called enteric hyperoxaluria ...

Phase 3 URIROX-1 Trial Achieves Primary Endpoint with Statistically Significant Reduction in Urinary Oxalate in Patients with Enteric Hyperoxaluria Phase 2 Study 206 Trial Demonstrates Substantial Plasma Oxalate Reduction in Patients with Enteric Hyperoxaluria and Advanced Chronic Kid...